| This week's sponsor is Kaiser Associates. | | | |
Today's Rundown Prothena, Celgene ink neuro R&D pact potentially worth $2B+ Alder CEO leaves as CGRP migraine race nears end With $125M in the bag, TCR2 advances lead T-cell programs [Sponsored] Digital R&D: Emerging technologies can boost clinical development Rocked by short attack, Proteostasis withdraws stock offering Beacon Capital’s incubator boosts New York City’s burgeoning biotech scene Novartis, Harvard ally to develop immuno-oncology implants Shire CEO sees Microsoft tie-up building momentum for faster rare disease diagnosis Featured Story | | | Tuesday, March 20, 2018 Celgene is handing over $150 million up front to Prothena to work on drugging three proteins that play a role in neurodegenerative diseases. The latter stands to pick up more than $2 billion in milestones and royalties if Celgene licenses global rights to all three programs. |
|
|
Top Stories Wednesday, March 21, 2018 Alder BioPharmaceuticals has parted company with its CEO. The decision, which Alder described as mutual, leaves the biotech without a permanent leader in the runup to filing for approval of migraine drug eptinezumab. Wednesday, March 21, 2018 TCR2's new capital will carry it into 2021, allowing it to bring its lead candidate, TC-210, through clinical proof of concept in multiple solid tumors. Monday, March 19, 2018 Clinical development has fallen behind in adopting digital technologies. While digital transformation can be a complex undertaking, the rewards are well worth the effort. The time for biopharma R&D to act is now. Learn more. Wednesday, March 21, 2018 Proteostasis Therapeutics has canned plans to sell shares after seeing its stock drop 26% in the wake of a short attack. The biotech unveiled plans to sell 9 million shares hours before Kerrisdale Capital’s attack and abandoned them hours after it hit. Wednesday, March 21, 2018 Beacon Capital's incubator will offer up to $50 million in seed funding, as well as office and lab space in a city aspiring to become the next big biotech hub. Wednesday, March 21, 2018 Novartis has teamed up with Harvard University to develop biomaterial-enabled immuno-oncology therapies. The Swiss pharma sees the collaboration yielding next-generation immunotherapies that use biodegradable implants and injectable systems to trigger long-lasting attacks on tumors. Wednesday, March 21, 2018 Slow diagnosis is all too common in the rare disease world, and Shire has forged a new partnership with Microsoft aimed at changing that. Along with patient organization alliance Eurordis, they've created a global "commission" to accelerate diagnosis and treatment. Resources Sponsored by: DocuSign Life science companies are experiencing a significant transformation in how they bring new products to market. Sponsored by: Reprints Desk The competitive landscape in medical device R&D is tough. And simply investing in R&D is no guarantee for profitability. So how do you accelerate time-to-market? Sponsored by: WCG Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals. Presented by: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Presented by: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented by: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented by: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented by: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored by: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Drug Approval, Manufacturing Quality & Regulation 2018 | Online BioBasics: Biotech for the Non-Scientist March 29-30, 2018 | Boston, MA Understanding Drug Pricing and Reimbursement April 3,2018 | Washington, DC IRT Europe – Interactive Response Technologies in Clinical Trials April 10th-11th, 2018 | Brussels, Belgium Field Service USA 2018 April 17-April 20, 2018 | JW Marriott Palm Desert Resort & Spa, CA
Drug Development Immersion April 25-26, 2018 | New York City Biotech for the Non-Scientist May 2-3, 2018 | San Diego, CA MIXiii-Biomed 2018 May 15-17, 2018 | Tel-Aviv, Israel BIO International Convention June 4-7, 2018 | Boston, MA
Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA | Register and start preparing Today! | 